ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Finance

Mizuho helping with $45B bridge loan for Allergan takeover

TOKYO -- Mizuho Bank is joining JPMorgan Chase and Wells Fargo in financing Actavis' purchase of fellow U.S. drugmaker Allergan, a sign of Japanese lenders' rising prominence in the deals business.

     The three banks will provide a $45 billion bridge loan for the $66 billion transaction.

     Japanese banks have almost always taken part in financing big U.S. corporate acquisitions only after their American peers have arranged bridge lending. This time, Mizuho is getting in on the deal from the interim financing stage and is expected to receive higher fees as a result.

     Actavis will eventually roll over most of the short-term loan into permanent financing, which will include debt and equity. Mizuho is looking to underwrite those securities sales through affiliates.

     Japanese banks are trying to augment their meager domestic profits by earning more overseas. Mizuho has been marketing itself to 120 or so major multinationals in hopes of landing business like the Actavis loan.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media